Table 2 Univariate analysis of prognostic factors affecting RFI, OS 1 , PFS and OS 2
Factors | Median RFI (months) | Pvalue* | Median OS1(months) | Pvalue* | Median PFS (months) | Pvalue* | Median OS2(months) | Pvalue* |
|---|---|---|---|---|---|---|---|---|
Age | ||||||||
≤ 50 | NA† | NA† | 10.0 | 0.868 | 36.5 | 0.966 | ||
> 50 | 10.9 | NR | ||||||
Menstruation status | ||||||||
Pre-menopausal | NA† | NA† | 9.5 | 0.985 | 36.5 | 0.565 | ||
Post-menopausal | 11.3 | NR | ||||||
Histology | ||||||||
IDC | 31.5 | 0.550 | 130.8 | 0.454 | 10.4 | 0.513 | 36.5 | 0.560 |
ILC | 36.4 | NR | 4.4 | NR | ||||
Others | 39.1 | 72.8 | 17.2 | 32.6 | ||||
Luminal subtype | ||||||||
Luminal A | 41.2 | <0.001 | 222.1 | 0.011 | 11.6 | 0.550 | 36.5 | 0.233 |
Luminal B | 24.2 | 71.7 | 9.4 | 32.6 | ||||
Adjuvant/neoadjuvant therapy | ||||||||
Only CT (± RT) | 17.7 | 0.138 | NR | 0.927 | 5.1 | 0.463 | NR | 0.639 |
Only HT (± RT) | 17.2 | NR | 23.2 | NR | ||||
CT + HT (± RT) | 36.1 | NR | 11.3 | NR | ||||
Therapy with TT | 28.9 | NR | 8.4 | NR | ||||
No | 28.9 | NR | 13.7 | NR | ||||
Relapse-free interval | ||||||||
≤ 2 years | NA | NA | 8.2 | 0.003 | 22.8 | 0.017 | ||
> 2 years | 12.9 | NR | ||||||
No. of metastatic sites | ||||||||
1 | NA | NA | 13.0 | 0.002 | NR | 0.032 | ||
2 | 16.5 | 32.6 | ||||||
≥ 3 | 8.4 | 25.1 | ||||||
Visceral metastasis | ||||||||
Yes | NA | NA | 9.0 | 0.035 | 36.5 | 0.393 | ||
No | 13.3 | NR | ||||||
First-line therapy after PET/CT | ||||||||
HT | NA | NA | 21.0 | 0.037 | NR | 0.019 | ||
CT (± TT) | 9.5 | 32.6 | ||||||
Baseline SUVmax | ||||||||
≤ 5.60 (Lowest tertile) | NA | NA | 19.2 | 0.002 | NR | 0.009 | ||
5.60 ~ 8.70 (Intermediate tertile) | 10.4 | 35.3 | ||||||
> 8.70 (Highest tertile) | 8.2 | 22.6 | ||||||